SCHEMBL4740965

SCHEMBL4740965

COc1nc(Nc2cccc(Cl)c2)c2cc[nH]c2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 4/20 0.60
TTBK2 Q6IQ55 3/20 0.60
EGFR P00533 4/20 0.53
SRC P12931 3/20 0.53
IGF1R P08069 2/20 0.53
KDR P35968 2/20 0.53
TEK Q02763 2/20 0.53
FLT4 P35916 1/20 0.53
PAK4 O96013 2/20 0.50
TNF P01375 1/20 0.49
FADS1 O60427 3/20 0.48
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GMNN O75496 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ABL1 P00519 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119696 0.78 TTBK1 (0.51) TTBK1TTBK2EGFRKDRFADS1
SCHEMBL5263613 0.75 EGFR (0.80) EGFRSRCIGF1RKDRTEK
SCHEMBL4738813 0.75 TTBK1 (1.00) TTBK1TTBK2EGFRFADS1KDM4E
Hydrochloric Acid SCHEMBL7018010 0.74 TTBK1 (0.97) TTBK1TTBK2EGFRFADS1KDM4E
SCHEMBL1612468 0.72 EGFR (0.41) TTBK1TTBK2EGFRSRCIGF1R
SCHEMBL5911706 0.69 EGFR (0.46) EGFRSRCKDRTNFFADS1
SCHEMBL4785920 0.69 TTBK1 (0.65) TTBK1TTBK2EGFRTNFFADS1
SCHEMBL5259470 0.69 EGFR (1.00) EGFRSRCIGF1RKDRTEK
SCHEMBL6218711 0.68 EGFR (0.70) EGFRSRCKDRTNFKDM4E
SCHEMBL5250340 0.68 TTBK1 (0.48) TTBK1TTBK2EGFRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 TTBK1 2062/4885TTBK2 1479/4885EGFR 1259/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL TTBK1 2633/4885TTBK2 2900/4885EGFR 2964/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG TTBK1 2093/4885TTBK2 1786/4885EGFR 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.